{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:55:08Z","timestamp":1793494508576,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.msard.2024.106161","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:57:45Z","timestamp":1731085065000},"page":"106161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Untackling the economics of multiple sclerosis: A systematic review of economic evaluations of disease-modifying therapies indicated for multiple sclerosis"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-720X","authenticated-orcid":false,"given":"Dr Panagiotis","family":"Petrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0142","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/13696998.2021.1927746","article-title":"Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden","volume":"24","author":"Acosta","year":"2021","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0120","first-page":"146","article-title":"Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran","volume":"20","author":"Ayati","year":"2021","journal-title":"Curr. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0135","first-page":"154","article-title":"Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis","volume":"20","author":"Ayati","year":"2021","journal-title":"Curr. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0126","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","article-title":"Cost-effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada","volume":"6","author":"Baharnoori","year":"2022","journal-title":"Pharmacoecon. Open."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0023","first-page":"245","article-title":"Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data","volume":"13","author":"Bell","year":"2007","journal-title":"J. Manage Care Pharm."},{"key":"10.1016\/j.msard.2024.106161_bib0100","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1007\/s10198-006-0379-5","article-title":"Costs and quality of life of multiple sclerosis in Sweden","volume":"7","author":"Berg","year":"2006","journal-title":"Eur. J. Health Econ."},{"issue":"10","key":"10.1016\/j.msard.2024.106161_bib0081","article-title":"Efficacy of fingolimod in pre-treated patients with disease activity: pooled analyses of FREEDOMS and FREEDOMS II (P3.174)","volume":"82","author":"Bergvall","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106161_bib0114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.vhri.2021.03.007","article-title":"Economic evaluation of cladribine tablets in patients with high disease activity\u2013relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia","volume":"25","author":"Bohlega","year":"2021","journal-title":"Value Health Reg. Issues."},{"key":"10.1016\/j.msard.2024.106161_bib0138","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsingremitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0083","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1017\/S0266462318003604","article-title":"Cost-utility analysis of multiple sclerosis treatment in Thailand","volume":"34","author":"Chanatittarat","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150703","article-title":"Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: a french societal perspective","volume":"11","author":"Chevalier","year":"2016","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","article-title":"Development and validation of a grading system for the quality of cost-effectiveness studies","volume":"41","author":"Chiou","year":"2003","journal-title":"Med. Care"},{"issue":"2","key":"10.1016\/j.msard.2024.106161_bib0124","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jval.2018.08.011","article-title":"Cost-effectiveness of alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States","volume":"22","author":"Chirikov","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2024.106161_bib0062","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106161_bib0054","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsingremitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106161_bib0118","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing remitting multiple sclerosis: a randomized controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106161_bib0117","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264123","article-title":"Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy","volume":"17","author":"Cortesi","year":"2022","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2024.106161_bib0057","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/brain\/122.4.625","article-title":"The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis","volume":"122","author":"Cottrell","year":"1999","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0146","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1017\/S0266462308080641","article-title":"Do individuals consider expected income when valuing health states?","volume":"24","author":"Davidsson","year":"2008","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0032","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10198-013-0478-z","article-title":"Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain","volume":"15","author":"Dembek","year":"2014","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis","volume":"43","author":"Duquette","year":"1993","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.msard.2024.106161_bib0086","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF03256144","article-title":"Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis","volume":"7","author":"Earnshaw","year":"2009","journal-title":"Appl. Health Econ. Health Policy."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0011","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J. Med. Libr. Assoc."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0122","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s41669-021-00282-7","article-title":"A model-based economic evaluation of cladribine versus alemtuzumab, ocrelizumab and natalizumab for the treatment of relapsing-remitting multiple sclerosis with high disease activity in Chile","volume":"5","author":"Espinoza","year":"2021","journal-title":"Pharmacoecon. Open."},{"key":"10.1016\/j.msard.2024.106161_bib0082","unstructured":"European Medicines Agency. Tecfidera: EPAR - Public assessment report. London, UK: EMA; 2013."},{"key":"10.1016\/j.msard.2024.106161_bib0017","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicenter randomised trial of interferon beta in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106161_bib0026","doi-asserted-by":"crossref","unstructured":"Feng Pan, Jo Wern Goh MS, Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States clinical therapeutics. Volume 34, Number 9, 2012.","DOI":"10.1016\/j.clinthera.2012.07.010"},{"key":"10.1016\/j.msard.2024.106161_bib0093","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106161_bib0051","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106161_bib0133","doi-asserted-by":"crossref","DOI":"10.1080\/13696998.2017.1357564","article-title":"Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon \u03b2-1a","author":"Frasco","year":"2017","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0039","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3111\/13696998.2013.792824","article-title":"A costeffectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden","volume":"16","author":"Fredrikson","year":"2013","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0107","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12913-019-4264-1","article-title":"Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy","volume":"19","author":"Furneri","year":"2019","journal-title":"BMC. Health Serv. Res."},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0102","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","article-title":"Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK","volume":"26","author":"Gani","year":"2008","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0113","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106161_bib0116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106161_bib0052","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106161_bib0064","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2024.106161_bib0091","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/archneur.1989.00520460093019","article-title":"Exacerbation rates and adherence to disease type in a prospectively followedup population with multiple sclerosis: implications for clinical trials","volume":"46","author":"Goodkin","year":"1989","journal-title":"Arch. Neurol."},{"issue":"9665","key":"10.1016\/j.msard.2024.106161_bib0144","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.106161_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/135245850000600207","article-title":"Cost and health related quality of life consequences of multiple sclerosis","volume":"6","author":"Grima","year":"2000","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40273-014-0150-1","article-title":"Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches","volume":"32","author":"Guo","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.msard.2024.106161_bib0055","series-title":"Fingolimod Reduces the Number of Severe Relapses in Patients with Relapsing Multiple Sclerosis: Results from Phase III TRANSFORMS and FREEDOMS Studies","first-page":"28","author":"Haas","year":"2011"},{"issue":"21","key":"10.1016\/j.msard.2024.106161_bib0003","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0131","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0112","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","article-title":"Health utilities for multiple sclerosis","volume":"19","author":"Hawton","year":"2016","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0007","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40258-013-0034-0","article-title":"Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis","volume":"11","author":"Hawton","year":"2013","journal-title":"Appl. Health Econ. Health Policy."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0034","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3111\/13696998.2016.1157080","article-title":"Costeffectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States","volume":"19","author":"Hernandez","year":"2016","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13696998.2016.1247712","article-title":"Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis","volume":"20","author":"Hernandez","year":"2017","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","article-title":"Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England","volume":"21","author":"Hettle","year":"2018","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0143","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","article-title":"Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine","volume":"33","author":"Hobart","year":"2019","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2024.106161_bib0066","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1185\/03007995.2013.863755","article-title":"Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison","volume":"30","author":"Hutchinson","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.msard.2024.106161_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40273-017-0577-2","article-title":"Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies","volume":"36","author":"Iannazzo","year":"2018","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.msard.2024.106161_bib0043","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0036","first-page":"87","article-title":"Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran","volume":"11","author":"Imani","year":"2012","journal-title":"Iran. J. Neurol."},{"key":"10.1016\/j.msard.2024.106161_bib0140","unstructured":"Institute for Clinical and Economic Review. Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Efectiveness and Value [Internet]. 2017 [cited 2023 May 28]. https:\/\/icer-review.org\/wp-content\/uploads\/2016\/08\/CTAF_MS_Final_Report_030617.pdf. Accessed 28 May 2023."},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0027","first-page":"1277","article-title":"The IFNB multiple sclerosis study group and the university of British Columbia MS\/MRI analysis group","volume":"45","year":"1995","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1191\/1352458505ms1211oa","article-title":"Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event","volume":"11","author":"Iskedjian","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106161_bib0044","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2298\/VSP0907556J","article-title":"Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition","volume":"66","author":"Jankovi\u0107","year":"2009","journal-title":"Vojnosanit. Pregl."},{"key":"10.1016\/j.msard.2024.106161_bib0028","doi-asserted-by":"crossref","unstructured":"John P. Caloyeras, Bin Zhang, Cheng Wang, Marianne Eriksson, Sten Fredrikson, Karola Beckmann, Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis clinical therapeutics. 34 (5) (2012).","DOI":"10.1016\/j.clinthera.2012.03.004"},{"key":"10.1016\/j.msard.2024.106161_bib0046","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebocontrolled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106161_bib0104","unstructured":"Johnson KP, Brooks BR, Cohen JA, et al. Extended use of from glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability."},{"key":"10.1016\/j.msard.2024.106161_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s001090050093","article-title":"The historical development of interferons as multiple sclerosis therapies","volume":"75","author":"Johnson","year":"1997","journal-title":"J. Mol. Med."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0068","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106161_bib0020","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106161_bib0137","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10127","key":"10.1016\/j.msard.2024.106161_bib0069","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a doubleblind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106161_bib0021","unstructured":"Kobelt G, Jo\u00a8nsson L, Fredrickson S et al (2001) Cost-utility analysis of interferon b-1b in the treatment of different types of multiple sclerosis. Stockholm School of Economics, SSE\/EFI Working Papers on Economics and Finance, Stockholm, No 459."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0037","first-page":"127","article-title":"Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data","volume":"18","author":"Kobelt","year":"2002","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0038","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10198-002-0163-0","article-title":"Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis","volume":"4","author":"Kobelt","year":"2003","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0101","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458507086667","article-title":"Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden","volume":"14","author":"Kobelt","year":"2008","journal-title":"Multiple Sclerosis"},{"issue":"8","key":"10.1016\/j.msard.2024.106161_bib0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106161_bib0024","unstructured":"Kobelt G. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Stockholm: Stockholm School of Economics; 2004. EFI Working Paper Series in Economics and Finance No. 594."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0025","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1007\/s10198-005-0289-y","article-title":"Economic evidence in multiple sclerosis: a review","author":"Kobelt","year":"2004","journal-title":"Eur. J. Health Econ."},{"issue":"2","key":"10.1016\/j.msard.2024.106161_bib0006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/erp.13.14","article-title":"Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review","volume":"13","author":"Koeser","year":"2013","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"key":"10.1016\/j.msard.2024.106161_bib0058","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awh721","article-title":"The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease","volume":"129","author":"Kremenchutzky","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.106161_bib0097","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vhri.2019.08.481","article-title":"Cost-effectiveness of natalizumab compared with fingolimod for relapsing-remitting multiple sclerosis treatment in Colombia","volume":"23","author":"Lasalvia","year":"2020","journal-title":"Value Health Reg. Issues."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10072-009-0015-0","article-title":"Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b","volume":"30","author":"Lazzaro","year":"2009","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0085","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3111\/13696998.2012.693553","article-title":"Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States","volume":"15","author":"Lee","year":"2012","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0078","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7175\/fe.v20i1.1437","article-title":"Cost-effectiveness analysis of dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis: an Italian societal perspective","volume":"20","author":"Mantovani","year":"2019","journal-title":"Farmeconomia. Health Econ. Therapeutic Pathways"},{"issue":"11","key":"10.1016\/j.msard.2024.106161_bib0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3111\/13696998.2015.1056794","article-title":"Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England","volume":"18","author":"Maruszczak","year":"2015","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104169","article-title":"Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon","volume":"67","author":"Matni","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0067","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","article-title":"Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States","volume":"19","author":"Mauskopf","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0109","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40258-019-00500-8","article-title":"Cost effectiveness of cladribine tablets for the treatment of relapsing-remitting multiple sclerosis in The Netherlands","volume":"17","author":"Michels","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.msard.2024.106161_bib0041","first-page":"24","article-title":"The Sonya Slifka longitudinal multiple sclerosis study: methods and sample characteristics","volume":"12","author":"Minden","year":"2006","journal-title":"MultScler"},{"key":"10.1016\/j.msard.2024.106161_bib0149","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1007\/s00415-022-11320-7","article-title":"Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy","volume":"269","author":"Moccia","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106161_bib0136","article-title":"A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK","author":"Montgomery","year":"2016","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0071","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/13696998.2022.2078103","article-title":"Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK","volume":"25","author":"Montgomery","year":"2022","journal-title":"J. Med. Econ."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0042","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/WNL.0b013e3182270402","article-title":"Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study","volume":"77","author":"Noyes","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0019","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1524-4733.2002.51052.x","article-title":"Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis","volume":"5","author":"Nuijten","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2024.106161_bib0056","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106161_bib0063","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib152","first-page":"53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J. Manag. Care Pharm."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0076","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2024.106161_bib0012","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0015","doi-asserted-by":"crossref","DOI":"10.3310\/hta2040","article-title":"A cost\u2013utility analysis of interferon beta for multiple sclerosis","volume":"2","author":"Parkin","year":"1998","journal-title":"Health Technol Assessment"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-0404.1982.tb03084.x","article-title":"Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980","volume":"65","author":"Patzold","year":"1982","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2024.106161_bib0148","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101514","article-title":"The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis","volume":"38","author":"Petruzzo","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0123","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/13696998.2020.1717499","article-title":"Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal","volume":"23","author":"Pinheiro","year":"2020","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0099","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0111","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14737167.2019.1635014","article-title":"Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain","volume":"20","author":"Poveda","year":"2020","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"issue":"9139","key":"10.1016\/j.msard.2024.106161_bib0074","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106161_bib0108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1352458511417481","article-title":"Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis","volume":"18","author":"Prosperini","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0047","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1524-4733.2004.75007.x","article-title":"Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis","volume":"7","author":"Prosser","year":"2004","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0098","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/13696998.2018.1560750","article-title":"Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran","volume":"22","author":"Rezaee","year":"2019","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0094","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12913-022-07495-4","article-title":"Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis","volume":"22","author":"Rezaee","year":"2022","journal-title":"BMC. Health Serv. Res."},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0103","article-title":"Interferon in relapsing- remitting multiple sclerosis","author":"Rice","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.106161_bib0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.49.2.358","article-title":"Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis","volume":"49","author":"Rudick","year":"1997","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0088","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of followup","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3111\/13696998.2012.654868","article-title":"Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients","volume":"15","author":"S\u00e1nchez-de la Rosa","year":"2012","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0077","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/03007995.2020.1747999","article-title":"Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis","volume":"36","author":"Samjoo","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"18","key":"10.1016\/j.msard.2024.106161_bib0127","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other diseasemodifying therapies for relapsing multiple sclerosis: a network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"J. Comp. Ef Res."},{"key":"10.1016\/j.msard.2024.106161_bib0065","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib151","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40273-021-01023-8","article-title":"Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland","volume":"39","author":"Schur","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.msard.2024.106161_bib0129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding","year":"2015","journal-title":"Pract. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2024.106161_bib0110","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","article-title":"Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"34","author":"Siddiqui","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0053","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clinthera.2017.01.028","article-title":"Cost-utility of first-line disease-modifying treatments for relapsing-remitting multiple sclerosis","volume":"39","author":"Soini","year":"2017","journal-title":"Clin. Ther."},{"issue":"7387","key":"10.1016\/j.msard.2024.106161_bib0106","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40273-021-01106-6","article-title":"Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom","volume":"40","author":"Spelman","year":"2022","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib150","first-page":"236","article-title":"The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis","volume":"26","author":"Synnott","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2024.106161_bib0049","unstructured":"TA303: Terifunomide for treating relapsing-remitting multiple sclerosis. 2014. at https:\/\/www.nice.org.uk\/Guidance\/ta303.)."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0092","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13696998.2018.1543189","article-title":"Cost effectiveness of lemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison","volume":"22","author":"Taheri","year":"2019","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.msard.2024.106161_bib0029","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1524-4733.2008.00485.x","article-title":"Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population","volume":"12","author":"Tappenden","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.msard.2024.106161_bib0014","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon \u00e2-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial","volume":"45","year":"1995","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2024.106161_bib0013","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon \u00e2-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0008","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40273-013-0063-4","article-title":"Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider","volume":"31","author":"Thompson","year":"2013","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.msard.2024.106161_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127960","article-title":"a network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon Beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis","volume":"10","author":"Tolley","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.msard.2024.106161_bib0084","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis","volume":"18","author":"Tramacere","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.106161_bib0096","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"9","author":"Tramacere","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2024.106161_bib0105","unstructured":"TYSABRI. EPAR summary for the public [report no. EMEA\/H\/C\/603]. London: European Medicines Agency, 2006."},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0147","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jval.2021.11.1363","article-title":"Effectiveness and cost-effectiveness of 360 disease-modifying treatment escalation sequences in multiple sclerosis","volume":"25","author":"Versteegh","year":"2022","journal-title":"Value Health"},{"issue":"14","key":"10.1016\/j.msard.2024.106161_bib0001","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S0317167100026573","article-title":"The natural history of multiple sclerosis","volume":"14","author":"Weinshenker","year":"1987","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.msard.2024.106161_bib0059","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0087","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2024.106161_bib0089","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: a geographically based study: II. Predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0139","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.msard.2024.106161_bib0050","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3111\/13696998.2016.1164174","article-title":"The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis in Canada","volume":"19","author":"Wenqing","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2024.106161_bib0119","doi-asserted-by":"crossref","unstructured":"Wong SL, Aldridge J, Hettle R, et al. Analysis of 6-month confirmed disability progression in RRMS patients treated with subcutaneous interferon beta-1a. Presented at: ACTRIMS Forum 2018; February 1-3, 2018; San Diego, CA. Abstract P047.","DOI":"10.1212\/WNL.90.15_supplement.P6.361"},{"issue":"3","key":"10.1016\/j.msard.2024.106161_bib0048","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40261-019-00750-3","article-title":"Cost-effectiveness of teriflunomide compared to interferon beta-1b for relapsing multiple sclerosis patients in China","volume":"39","author":"Xu","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.msard.2024.106161_bib0004","article-title":"Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature","volume":"2012","author":"Yamamoto","year":"2012","journal-title":"Autoimmune Dis."},{"issue":"10","key":"10.1016\/j.msard.2024.106161_bib0132","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/13696998.2017.1355310","article-title":"Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis","volume":"20","author":"Yang","year":"2017","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.msard.2024.106161_bib0061","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40263-014-0207-x","article-title":"Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-\u03b21a in relapsing-remitting multiple sclerosis","volume":"29","author":"Zhang","year":"2015","journal-title":"CNS. Drugs"},{"issue":"12","key":"10.1016\/j.msard.2024.106161_bib0141","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s40263-018-0566-9","article-title":"Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: a cost-utility analysis","volume":"32","author":"Zimmermann","year":"2018","journal-title":"CNS. Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:56:38Z","timestamp":1757357798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824007375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":150,"alternative-id":["S2211034824007375"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106161","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Untackling the economics of multiple sclerosis: A systematic review of economic evaluations of disease-modifying therapies indicated for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106161"}}